Staying vigilant about these signs can help you seek medical help immediately and prevent irreversible liver damage.

Fatty liver disease is a silent disease that can develop gradually without showing symptoms at first. However, if not detected and treated in time, it can progress to serious stage ...

At the annual Liver Meeting sponsored by the American Association for the Study of Liver Diseases (AASLD), AASLD President Grace L. Su, MD, of the University of Michigan in Ann Arbor, highlighted ...

Nonalcoholic steatohepatitis (NASH), now called MASH, happens when fat accumulates in the liver and causes inflammation. Asking questions during doctor visits can help provide you with information and ...

Semaglutide reduced liver fibrosis and resolved MASH in the ESSENCE trial, offering dual hepatic and metabolic benefits. Read ...

A new study has revealed that a medication for diabetes is effective in alleviating non-alcoholic steatohepatitis (NASH). Severance Hospital announced on the 28th that a research team—including ...

Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter, randomized, ...

Adult patients with metabolic dysfunction–associated steatohepatitis (MASH) and moderate or advanced liver fibrosis showed improved liver histology with a once-weekly dose of semaglutide (Wegovy), an ...

A South Korean research team has developed a diagnostic monitoring technology for non-alcoholic steatohepatitis (NASH) using magnetic resonance imaging (MRI). This non-invasive method allows for ...